Hundreds of Millions in Series D Funding: Insurtech Capital Bets Big on Tricuspid Valve Intervention Leader Huihe Medical
H&H Healthcare
R&D and Producer of Interventional Medical Devices for Heart Disease
Heart Future
Recently,Shanghai Huihe Healthcare Technology Co., Ltd.("HuiHe Healthcare"") Announced CompletionHundreds of Millions of Dollars in Series DFinancing was strategically led by Taiping Healthcare Fund, with follow-up investment from existing shareholder Sherpa Investment.
This is another key capital move for the company since the completion of its C+ round financing in 2022, and it also marks the entry of its core product into the stage of large-scale commercial application.
With the deep involvement of insurance funds, the "payment-technology-clinical" collaborative pathway in the structural heart disease sector is gradually taking shape.
# DRound of Financing Completed: Insurance Funds Move into Structural Heart Disease
According to the information disclosed by HuiHe Healthcare, this roundDRound of financing byTaiping Healthcare Fund StrategyLeading investment, existing shareholdersSuzhou Sherpa Phase II Equity Investment Partnership (Limited Partnership)Continuous follow-up investment.
This is one of the important layouts of Taiping Medical Health Fund in the field of interventional treatment for structural heart disease.
Against the backdrop where medical device investment and financing as a whole are becoming more rational, and capital is paying more attention to certainty and realization paths,DRound financing itself has a clear signaling significance:
It usually occurs when a company's core product completes critical clinical validation, gains approval for market entry, and enters the commercial expansion phase, serving asComprehensive recognition of the "technology-registration-market" full-chain capabilities.
More noteworthy is that,The lead investor of this round of financing comes from the insurance system capital.。
In recent years, the participation of insurance funds in the medical and health field has evolved from early-stage financial investments to strategic layouts with stronger industrial synergy.
Its long-term, cross-cycle, and stable capital attributes, along with high-end medical devices"The characteristics of a long R&D cycle, slow clinical validation, and steep commercialization ramp are highly matched."
For the track of structural heart disease, which highly relies on real-world clinical outcomes, long-term patient benefits, and support from the payment system, the entry of insurance capital often implies higher requirements for product safety, efficacy stability, and long-term clinical value.
# Why HuiHe Healthcare: The Pathway Judgment Behind Capital Choice
Taiping Healthcare Fund mentioned in its public statements that its investment logic has always adhered to"Research First" – Focusing on the Most Innovative and Commercially Promising Medical Technologies Globally.
The core reasons why HuiHe Healthcare has gained their favor lie in two aspects:Original Technical PathwayAndCore products that have entered the commercial validation stage。
In the field of structural heart disease intervention, the technical pathways for mitral and aortic valves are relatively mature, while the tricuspid valve has long been referred to as"The Neglected Valve"
A large number of patients suffer from tricuspid regurgitation, but the surgical risk is high, and the rate of traditional surgical intervention is low, with significant unmet clinical needs persisting over the long term.
Over the past decade, global interventional device companies have conducted extensive exploration in the tricuspid valve field, but only a few products have achieved stable commercialization.
Against this backdrop, companies that can successfully navigate the path from original innovation, clinical validation to registration and market launch in the tricuspid valve sector are naturally scarce.
The core competitiveness of HuiHe Healthcare is mainly reflected in itsAn Original Breakthrough in the Tricuspid Annuloplasty Repair Technology PathwayUp.
# Clinical Needs Return to the Starting Point: Why Is Tricuspid Regurgitation So Difficult to Solve?
From the perspective of disease burden, tricuspid regurgitation is not"Rare Diseases".
With the aging population and the increasing number of patients with atrial fibrillation and heart failure, the incidence of moderate to severe tricuspid regurgitation in the elderly continues to rise.
▲Characteristics of Tricuspid Regurgitation in the Asia-Pacific Region in the Journal 《JACC: Asia》
Unlike the aortic and mitral valves, the tricuspid valve has long faced a triple reality dilemma:
Poor surgical tolerance in patients:Often complicated by right heart failure, liver and kidney dysfunction, with high surgical risk;
Complex valve anatomy:The annulus is irregular with significant dynamic morphological changes;
Traditional surgical methods are highly invasive:Limited clinical accessibility.
Therefore, a large number of patients remain in the condition for a long time"Diagnosis without Effective Intervention"The status.
This is also why the tricuspid valve is considered a key area in structural heart disease."The Last Great Blue Ocean"The root cause.
But at the same time, it is also one of the tracks with the highest technical difficulty and the most failed cases.
In terms of surgical volume, according to Sullivan data forecasts,The Global Volume of Transcatheter Tricuspid Valve Interventions Will Increase from 340 Cases in 2021 to 450,000 Cases by 2030; andThe number of transcatheter tricuspid valve interventions in China is expected to increase significantly starting from 2023, rising from 600 cases to an estimated 200,000 cases by 2030.。
▲ Originated fromFrost & Sullivan
# K-Clip®：From Surgical LogicOriginal Pathway for Departure Intervention
2025 Year3 Month, the National Medical Products Administration approvedK-Clip®Innovative Product Registration Application for Transcatheter Tricuspid Annuloplasty System.
This not only makes itOne of the world's first commercially available tricuspid annuloplasty interventional products, which also marks a substantial breakthrough achieved by domestically original technology in this field.
More importantly, after being approved, the product did not remain stagnant."Symbolic Application" Phase.
According to the company's disclosed information,K-Clip® Has been commercially applied at scale in multiple medical centers in China, entering the real-world clinical validation phase.
For high-difficulty structural heart disease interventional products, market entry is just the first step.
What truly determines its long-term value is:
Surgical Reproducibility;
Doctor Learning Curve;
Complication Control Ability;
Long-term follow-up results.
These factors are gradually emerging during the commercialization process.
K-Clip®Transcatheter Tricuspid Annuloplasty System
According to the official information of the company,K-Clip®YesThe World's First Transcatheter Tricuspid Annuloplasty Repair System, through minimally invasive surgical methods, reproduced the classic surgical procedure.Kay’s Surgery: Folding and resizing the enlarged tricuspid valve annulus to repair tricuspid regurgitation. The procedure is minimally invasive, with quick recovery and an average operation time of approximately 30 minutes.
The R&D process is as follows:
In June 2018, HuiHe Healthcare drew inspiration from a wine opener and designed the K-Clip.®。
In April 2021, the team of Academician Ge Junbo from Zhongshan Hospital, Fudan University completed K-Clip.®The first human implantation.
In October 2021, K-Clip®Enter the National Medical Products Administration (NMPA) Special Approval "Green Channel" for Innovative Medical Devices.
In May 2022, K-Clip®LaunchedTristar I Single-Arm Target Value Registration Clinical Study.
In March 2023, the Tristar II randomized parallel controlled registration clinical study was initiated.
Completed 1-year follow-up in 2024, and the results showed K-Clip®Can significantly reduce the severity of tricuspid regurgitation and improve cardiac function.
K-Clip®Provides the preferred treatment method for patients with severe tricuspid regurgitation primarily characterized by annular dilation., and in patients with severe right heart dysfunction, it can be used as"Bridge treatment" for TEER or TTVR surgery to prevent acute right heart failure.
# Capital Synergy Perspective: Why Insurance Funds Are Worth Attention
The participation of Taiping Healthcare Fund gives this round of financing significance beyond a mere capital injection.
From the perspective of industrial logic, insurance, as an important component of the medical payment system, has a natural connection with the treatment of structural heart disease:
Patients are mostly those with chronic diseases;
The treatment outcome is highly correlated with long-term quality of life;
Payment Decisions Focus More on Long-term Costs- Effect Ratio.
Within this framework, innovative interventional devices that can demonstrate their long-term value in reducing readmission rates and improving cardiac function will more easily enter the positive cycle of the payment system.
This also paves the way for the future"Insurance+Medical Device+Clinical Pathway OptimizationThe collaborative exploration provides a real-world sample.
# Company Profile: HuiHe Healthcare's Long-term Positioning
HuiHe HealthcareIs aFocus on the research, development, production, and commercialization of cardiovascular interventional medical devices.High-tech enterprise, founded inIn May 2019, headquartered in Songjiang District, Shanghai, with the core concepts of "medical-engineering integration" and "original innovation," committed to promoting China-produced high-end medical devices globally.
In its development path, HuiHe Healthcare has not chosen the strategy of "multi-point expansion", but has long focused on the highly challenging niche track in structural heart disease, forming a relatively clear technical depth.
Core Product
K-Clip®Transcatheter Tricuspid Annuloplasty System：The world's first tricuspid valve interventional repair system, replicating classic surgical procedures, repairs tricuspid regurgitation through minimally invasive surgery.
C-Wave®Intravascular Shockwave Catheter：The first shock wave catheter in China with both coronary and peripheral indications, adopting a uniqueS-shaped spiral electrode design ensures more balanced energy and more stable discharge. Approved for marketing by NMPA in 2024.
Vispearl®Visible Drug-Loaded Embolic Microspheres：Full-size visible drug-eluting embolic microspheres for tumor interventional therapy.
S-Wan™ Dual-Control Bend Catheter Sheath：Bipolar Steerable Sheath for Complex Interventional Procedures.
# Conclusion: The Mutual Selection of Patient Capital and Patient Technology
Interventional treatment for structural heart disease has never been a track that yields quick returns.
It requires long-term technical accumulation, rigorous clinical validation, and a full understanding of the risk of failure.
In such a field, the relationship between capital and enterprises is essentially a"Two-way Screening".
HuiHe Healthcare CompletesD A round of financing does not mean the end of the story, but rather the beginning of another journey that is more realistic and challenging —
That is, continuously demonstrating the value of technology in the real world.
The entry of insurance funds may also herald the interventional field of structural heart disease,Transferring from"Technology Competition" Towards "Long-term Value Competition".
GCC2025
Full Disease Solutions for Cardiovascular Devices
Statement
Content Statement:"Heart of the Future" tracks global medical technology advancements, aiming to disseminate technical and industry knowledge. All content is intended for professional exchange and academic discussion only, and does not constitute medical advice or commercial promotion. Information about companies, products, and registrations mentioned in the text is sourced from publicly available materials or verified channels. If there are any errors or omissions, please contact us for corrections. Email: jacky@suribot.com
Copyright Statement:"The Future of the Heart" original manuscripts are owned by Beijing Siyu Bot Technology Co., Ltd. Without authorization, they cannot be reprinted, excerpted, or mirrored to other websites, official accounts, or commercial platforms; for reprinting, please contact the backstage to obtain authorization. For unauthorized full-text reprinting, rewriting, or paraphrasing, this platform reserves the right to pursue legal responsibilities.
